Evaluation of Hormone Quantification as an Orientation Screening in the Diagnosis of Hormone-Dependent Breast Cancers in Women in Abidjan, Côte d'Ivoire
Franck Arnaud Gnahoré Djéda *
Molecular Genetics Platform, Institut Pasteur de Côte d'Ivoire, Côte d'Ivoire and Laboratory of Biology and Health, UFR Biosciences, Université Félix Houphouët Boigny, Côte d'Ivoire.
Valérie Carole M’Bengue Gbonon
Molecular Genetics Platform, Institut Pasteur de Côte d'Ivoire, Côte d'Ivoire.
Flore Bernadette Diplo
Molecular Genetics Platform, Institut Pasteur de Côte d'Ivoire, Côte d'Ivoire.
Safiatou Coulibaly
Molecular Genetics Platform, Institut Pasteur de Côte d'Ivoire, Côte d'Ivoire.
Akandji Osseni
Cancerology Department, CHU of Treichville, Côte d'Ivoire.
Mamadou Sekongo
Department of Training and Research, National Blood Transfusion Centre, Côte d'Ivoire.
Jean David N’Guessan
Laboratory of Biology and Health, UFR Biosciences, Université Félix Houphouët Boigny, Côte d'Ivoire.
Joseph Allico Djaman
Laboratory of Biology and Health, UFR Biosciences, Université Félix Houphouët Boigny, Côte d'Ivoire.
Mireille Dosso
Molecular Genetics Platform, Institut Pasteur de Côte d'Ivoire, Côte d'Ivoire.
*Author to whom correspondence should be addressed.
Abstract
Aim: Estrogens and progesterone are essential for breast development in women. Paradoxically they promote the development of breast cancer, through the stimulation and proliferation of cells by the action of hormone receptors. In Côte d'Ivoire, more than half of all diagnosed cases of breast cancer are hormone-dependent. Because of the link between female hormones and breast cancer, the consideration of certain factors, such as the period of influence of hormones (estrogen and progesterone) as well as their quantification, could be considered in orientation screening for hormone-dependent breast cancer.
Methodology: A case-control study conducted at the Cancerology Department of the Treichville University Hospital, the National Blood Transfusion Centre, and the Pasteur Institute of Côte d'Ivoire recruited 85 participants, including 39 cases and 46 non-menopausal and menopausal controls. Socio-demographic information and the participants' clinical status were collected through a questionnaire and consultation of the medical file. Blood samples were taken in dry red tubes with a coagulation activator on the day of inclusion for postmenopausal women and during the follicular phase for non-menopausal women (between days 4 and 7 of the menstrual cycle). The quantification of hormones (estrogen, progesterone, FSH, and LH) was performed by immunoassay on the Cobas e411 Analyser®.
Results: Postmenopausal cases had early menarche (13 years) and late menopause (52.46 years) compared to controls and also had slightly higher mean plasma oestradiol 2 and progesterone levels (P=0.04; P=0.017). Among these cases, those with ER+ tumors had slightly higher mean plasma oestradiol-2 levels (15.28 pg/mL) than those with ER- tumors (9.20 pg/mL) (P=0.03).
Conclusion: The epidemiological investigation and the quantification of hormones in the participants' blood plasma revealed a positive association between the period of influence of these hormones, their concentrations, and hormone-dependent breast cancer in postmenopausal women.
Keywords: Breast cancer, estradiol-2, progesterone, hormone receptors, immunohistochemistry, biomarker
How to Cite
Downloads
References
Sancho-Garnier H, Colonna M. Breast cancer epidemiology. Medical Press. 2019;48(10):1076–84.
Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48.
Global Cancer Observatory [Internet]. Available from: https://gco.iarc.fr/Accessed on 2021 Feb 5
Gompel A. [Hormone and breast cancer]. Presse Medicale Paris Fr 1983. 2019;48(10):1085–91.
Denver N, Khan S, Homer NZM, MacLean MR, Andrew R. Current strategies for quantification of estrogens in clinical research. J Steroid Biochem Mol Biol. 2019;192:105373.
Hetemäki N, Savolainen-Peltonen H, Tikkanen MJ, Wang F, Paatela H, Hämäläinen E et al. Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women. J Clin Endocrinol Metab. 2017;102(12): 4588–95.
Coumoul X, Barouki R. Génotoxicité des métabolites des œstrogènes et cancers. médecine/sciences [Internet]. 2002;18(1):86–90. Available:https://www.medecinesciences.org/articles/medsci/abs/2002/01/medsci2002181p86/medsci2002181p86.html Accessed on 2021 Nov 30
Starek-Świechowicz B, Budziszewska B, Starek A. Endogenous estrogens—breast cancer and chemoprevention. Pharmacol Rep [Internet]. 2021;73(6):1497–512. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599256/
Access on 2023 Apr 16
Cenciarini ME, Proietti CJ. Molecular mechanisms underlying progesterone receptor action in breast cancer: Insights into cell proliferation and stem cell regulation. Steroids. 2019;152:108503.
Santen RJ, Stuenkel CA, Yue W. Mechanistic effects of estrogens on breast cancer. Cancer J Sudbury Mass. 2022;28(3):224–40.
Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol Lond Engl. 2014;10(14):2293–301.
Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.
Effi AB, Koffi KE, Aman NA, Doukouré B, N’dah KJ, Koffi KD et al. Épidémiologie descriptive des cancers en Côte d’Ivoire. Bull Cancer (Paris) [Internet]. 2013 Feb;100(2):119–25.
Available:https://www.sciencedirect.com/science/article/pii/S0007455115302678 Access on 2021 Feb 5
Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women. BMC Clin Pathol [Internet]. 2019;19(1):1–6.
Available:https://bmcclinpathol.biomedcentral.com/articles/10.1186/s12907-018-0081-4 Accessed on 2022 Feb 1
Yaghoobi V, Martinez-Morilla S, Liu Y, Charette L, Rimm DL, Harigopal M. Advances in quantitative immunohistochemistry and their contribution to breast cancer. Expert Rev Mol Diagn. 2020;20(5):509–22.
Stemp M, McClements A, Sykes P, Chapple V, Matson P. The measurement of oestradiol, progesterone, LH, FSH and hCG for assisted reproduction: A comparison of the Siemens Centaur CP and Roche e411 automated analysers. Asian Pac J Reprod. 2013;2:321–5.
Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N’da G et al. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: A population-based registry study. Int J Cancer. 2020;146(5):1208–18.
Elwood JM, Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer. 1980;42(5):635–44.
Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59(4):651–72.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer Oxf Engl 1990. 2013;49(6):1374–403.
Collaborative group on hormonal factors in breast cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.
Dunneram Y, Greenwood DC, Cade JE. Diet, menopause and the risk of ovarian, endometrial and breast cancer. Proc Nutr Soc. 2019;78(3):438–48.
Russo J, Moral R, Balogh GA, Mailo D, Russo IH. The protective role of pregnancy in breast cancer. Breast Cancer Res BCR. 2005;7(3):131–42.
ChenMD WY. Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab [Internet]. 2008;22(4):573–85. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2599924/
Accessed on 2023 Mar 28
Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709–22.
Ambrosone CB, Zirpoli G, Ruszczyk M, Shankar J, Hong CC, McIlwain D et al. Parity and breastfeeding among african-american women: differential effects on breast cancer risk by estrogen receptor status in the women’s circle of health study. Cancer Causes Control Ccc [Internet]. 2014;25(2):259–65. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903305/ Accessed on 2023 Mar 30
Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, et al. Parity, Lactation, and Breast Cancer Subtypes in African American Women: Results from the AMBER Consortium. JNCI J Natl Cancer Inst [Internet]. 2014;106(10):dju237. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271113/ Access on 2023 Mar 30
Akoko LO, Rutashobya AK, Lutainulwa EW, Mwanga AH, Kivuyo SL. The effect of reproductive, hormonal, nutritional and lifestyle on breast cancer risk among black Tanzanian women: A case control study. PLoS ONE [Internet]. 2022;17(2):e0263374. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827470/
Access on 2023 Mar 30
Effi AB, Aman NA, Koui BS, Koffi KD, Traoré ZC, Kouyate M. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast. BMC Cancer [Internet]. 2017;17:115. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297122/
Access on 2023 Mar 28
Aka E, Horo A, Koffi A, Fanny M, Didi-Kouko C, Nda G, et al. Expérience africaine monocentrique de la prise en charge personnalisée des cancers du sein à Abidjan : défis et perspectives. Gynecology Obstetrics Fertil Senology [Internet]. 2021;49(9):684–90.
Available:https://www.sciencedirect.com/science/article/pii/S2468718921000507 Access on 2023 Mar 30
Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006;98(19):1406–15.
Sturgeon SR, Potischman N, Malone KE, Dorgan JF, Daling J, Schairer C et al. Serum levels of sex hormones and breast cancer risk in premenopausal women: A case–control study (USA). Cancer Causes Control [Internet]. 2004;15(1):45–53. Available:https://doi.org/10.1023/B:CACO.0000016574.79728.11 Access on 2023 Mar 8
Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat [Internet]. 2013;137(3):883–92. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582409/ Access on 2022 Feb 23
Key T, Appleby P, Barnes I, Reeves G, Endogenous hormones and breast cancer collaborative group. endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606–16.
Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S et al. Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in Libya. J Cancer [Internet]. 2012;3:421–31. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471082/
Access on 2022 Feb 23
Ohene-Yeboah M, Adjei E. Breast cancer in Kumasi, Ghana. Ghana Med J [Internet]. 2012;46(1):8–13. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353503/ Access on 2023 Mar 31
Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21–7.
Toure M, Nguessan E, Bambara AT, Kouassi YKK, Dia JML, Adoubi I. Factors related to late diagnosis of breast cancer in sub-Saharan Africa: case of Côte d'Ivoire. Obstetric gynecology Fertil [Internet]. 2013;41(12):696– 700. Available:https://www.sciencedirect.com/science/article/pii/S1297958913002634 Access on 2022 Feb 23